Technical Analysis for MYGN - Myriad Genetics, Inc.

Grade Last Price % Change Price Change
grade F 12.19 -1.61% -0.20
MYGN closed down 1.61 percent on Friday, August 7, 2020, on 39 percent of normal volume.
Earnings due: Aug 11
*** please verify all earnings dates ***

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Up
Historical MYGN trend table...

Date Alert Name Type % Chg
Overbought Stochastic Strength 0.00%
Stochastic Sell Signal Bearish -1.61%
MACD Bullish Centerline Cross Bullish -1.61%
Upper Bollinger Band Walk Strength -1.61%
Overbought Stochastic Strength -1.61%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -2.17%
NR7 Range Contraction -2.17%
Stochastic Reached Overbought Strength -2.17%
Upper Bollinger Band Walk Strength -2.17%
Weak + Overbought Other -2.17%

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Myriad Genetics, Inc., a molecular diagnostic company, focuses on the development and marketing of predictive medicine, personalized medicine, and prognostic medicine tests primarily in the United States. The company's molecular diagnostic tests are designed to analyze genes, their mutations, expression levels, and proteins to assess an individual's risk for developing disease later in life; determine a patient's likelihood of responding to a particular drug; and assess a patient's risk of disease progression and disease recurrence. It offers various molecular diagnostic tests that include BRACAnalysis and BART, which are predictive medicine tests for hereditary breast and ovarian cancer; COLARIS predictive medicine test for hereditary colorectal and uterine cancer; COLARIS AP predictive medicine test for hereditary colorectal cancer; MELARIS predictive medicine test for hereditary melanoma; PANEXIA, a predictive medicine test for pancreatic cancer; PREZEON, a personalized and prognostic medicine test for cancer; Prolaris, a prognostic medicine test for prostate cancer; and TheraGuide 5-FU, a personalized medicine test for drug toxicity. The company, through its subsidiary, Myriad RBM, Inc., also offers biomarker discovery and companion diagnostic services to the pharmaceutical, biotechnology, and medical research industries that include multi-analyte profile testing services; multiplexed immunoassay kits; and TruCulture, a self-contained whole blood culture that allows pharmaceutical and biotechnology companies to identify drug toxicity prior to human trials. Myriad Genetics, Inc. was founded in 1991 and is headquartered in Salt Lake City, Utah.
Medicine Biotechnology Cancer Clinical Medicine Disease Prostate Cancer Ovarian Cancer Medical Genetics Diagnostic Tests Pancreatic Cancer Biomarkers Personalized Medicine Chemical Pathology

Is MYGN a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 47.1
52 Week Low 9.24
Average Volume 1,163,269
200-Day Moving Average 19.06
50-Day Moving Average 12.56
20-Day Moving Average 11.97
10-Day Moving Average 12.11
Average True Range 0.58
ADX 12.61
+DI 17.63
-DI 17.18
Chandelier Exit (Long, 3 ATRs ) 10.91
Chandelier Exit (Short, 3 ATRs ) 12.79
Upper Bollinger Band 12.61
Lower Bollinger Band 11.34
Percent B (%b) 0.67
BandWidth 10.58
MACD Line 0.01
MACD Signal Line -0.10
MACD Histogram 0.1081
Fundamentals Value
Market Cap 835.75 Million
Num Shares 68.6 Million
EPS 0.32
Price-to-Earnings (P/E) Ratio 38.09
Price-to-Sales 3.01
Price-to-Book 2.98
PEG Ratio 3.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 12.87
Resistance 3 (R3) 12.91 12.72 12.75
Resistance 2 (R2) 12.72 12.55 12.70 12.71
Resistance 1 (R1) 12.46 12.45 12.37 12.42 12.68
Pivot Point 12.27 12.27 12.23 12.25 12.27
Support 1 (S1) 12.01 12.10 11.92 11.97 11.70
Support 2 (S2) 11.82 12.00 11.80 11.67
Support 3 (S3) 11.56 11.82 11.63
Support 4 (S4) 11.52